NGLFINE2023-04-012023-06-30 NGLFINE2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member NGLFINE2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524774 NGLFINE NOTLISTED NGL Fine-Chem Limited Equity 2023-04-01 2024-03-31 2023-08-04 2023-07-26 INR Lakhs First quarter 17:30:00 18:50:00 2023-08-04 2023-08-04 Not applicable Single segment PHARMACEUTICALS 2023-04-01 2023-06-30 Unaudited Standalone 691135000.00 38023000.00 729158000.00 315370000.00 0.00 16538000.00 97939000.00 2429000.00 19989000.00 185283000.00 637548000.00 91610000.00 0.00 91610000.00 11838000.00 1716000.00 13554000.00 0.00 78056000.00 0.00 0.00 0.00 0.00 78056000.00 -2316000.00 75740000.00 0.00 0.00 30890000.00 5 12.63 12.63 0.00 0.00 12.63 12.63 1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 4th August, 2023. These results were subjected to Limited Review by the Statutory Auditors of the Company. 2 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time 3 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 Operating Segment notified pursuant to Companies (Indian Accounting Standards) Rule 2015. 4 Previous period figures have been regrouped/rearranged wherever necessary. 5 The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full year ended March 31, 2023 and the published year to date figures upto the the third quarter ended December 31, 2022 of the relevant financial year Other Expenses 185283000.00 3095000.00 -779000.00